- Home
- PMCB vs ADXN Comparison
PMCB vs ADXN Comparison
Compare PMCB & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- ADXN
- Stock Information
- Founded
- PMCB 1996
- ADXN 2002
- Country
- PMCB United States
- ADXN Switzerland
- Employees
- PMCB N/A
- ADXN N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- ADXN Health Care
- Exchange
- PMCB Nasdaq
- ADXN Nasdaq
- Market Cap
- PMCB 7.6M
- ADXN 8.1M
- IPO Year
- PMCB N/A
- ADXN N/A
- Fundamental
- Price
- PMCB $1.05
- ADXN $9.00
- Analyst Decision
- PMCB
- ADXN Strong Buy
- Analyst Count
- PMCB 0
- ADXN 1
- Target Price
- PMCB N/A
- ADXN $30.00
- AVG Volume (30 Days)
- PMCB 8.5K
- ADXN 10.6K
- Earning Date
- PMCB 08-12-2025
- ADXN 06-19-2025
- Dividend Yield
- PMCB N/A
- ADXN N/A
- EPS Growth
- PMCB N/A
- ADXN N/A
- EPS
- PMCB 1.29
- ADXN 0.10
- Revenue
- PMCB N/A
- ADXN $278,508.00
- Revenue This Year
- PMCB N/A
- ADXN $86.57
- Revenue Next Year
- PMCB N/A
- ADXN N/A
- P/E Ratio
- PMCB $0.82
- ADXN $0.72
- Revenue Growth
- PMCB N/A
- ADXN N/A
- 52 Week Low
- PMCB $1.00
- ADXN $6.51
- 52 Week High
- PMCB $2.42
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- PMCB 47.26
- ADXN 55.39
- Support Level
- PMCB $1.00
- ADXN $8.02
- Resistance Level
- PMCB $1.07
- ADXN $9.78
- Average True Range (ATR)
- PMCB 0.05
- ADXN 0.73
- MACD
- PMCB 0.01
- ADXN 0.02
- Stochastic Oscillator
- PMCB 39.78
- ADXN 32.94
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.